Benzinga.com

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity

On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
Benzinga.com

EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
Business Wire

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...
AOL

Beyond the brand names: Everything you need to know about Ozempic and other GPL-1 medications

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...